How a potential $1.2 billion cancer drug deal helps this East Bay biotech target diseases of aging


The deal is the third over the past year by the team behind Teneobio.

Previous How a potential $1.2B cancer drug deal helps this Newark biotech target diseases of aging
Next Mayo Clinic, Allina Health, North Memorial, Maple Grove Hospital score high on Fortune/Merative Top 100 Hospitals list